8.54
-0.64 (-6.97%)
8.63
+0.09 (+1.05%)
ChartMill assigns a Buy % Consensus number of 100% to CATB. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 24.23. This target is 183.67% above the current price.
- CATB was analyzed by 4 analysts. The buy percentage consensus is at 100. So analysts seem to be very confident about CATB.
- In the last month the buy percentage rose by 13 points. So the trust of analysts is improving.
- Only 4 analysts analyzed CATB. So this is just the average opinion of a couple of analysts.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2021-09-02 | Wedbush | Initiate | Outperform |
| 2021-08-25 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2021-05-12 | Ladenburg Thalmann | Initiate | Buy |
| 2021-03-11 | Oppenheimer | Upgrade | Perform -> Outperform |
Catabasis Pharma / CATB FAQ
Can you provide the average price target for Catabasis Pharma stock?
4 analysts have analysed CATB and the average price target is 24.23 null. This implies a price increase of 183.67% is expected in the next year compared to the current price of 8.54.
What is the consensus rating for CATB stock?
The consensus rating for Catabasis Pharma (CATB) is 100 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for CATB stock?
The number of analysts covering Catabasis Pharma (CATB) is 4.